Log In
BCIQ
Print this Print this
 

BRM132

  Manage Alerts
Collapse Summary General Information
Company BRIM Biotechnology Inc.
DescriptionCombination of a recombinant protein based on the adenovirus serotype 35 fiber knob plus rituximab
Molecular Target
Mechanism of Action 
Therapeutic ModalityBiologic: Protein
Latest Stage of DevelopmentPreclinical
Standard IndicationB cell lymphoma
Indication DetailsTreat B cell lymphoma
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today